Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients
Xueke Tian, Congmin Zhang, Zifei Qin, Dao Wen Wang, Jing Yang, Xiaojian Zhang
Abstract
Voriconazole (VRC), a first-line agent for the treatment of invasive fungal infections, is mainly metabolized by human cytochrome P450 (CYP) 2C19. In this study, a retrospective analysis was performed to investigate the key factors that influence the plasma trough concentration ( C min ) of VRC, and an appropriate dosing regimen for pediatric patients was drafted subsequently.
Topics & Concepts
CminCYP2C19VoriconazolePharmacologyMedicinePharmacokineticsTherapeutic drug monitoringDosingDrugDrug interactionInternal medicineCmaxCytochrome P450MetabolismAntifungalDermatologyAntifungal resistance and susceptibilityFungal Infections and StudiesInfectious Diseases and Mycology